Creative Planning Takes $254,000 Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Creative Planning purchased a new position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 7,921 shares of the company’s stock, valued at approximately $254,000.

A number of other hedge funds also recently modified their holdings of SWTX. First Horizon Advisors Inc. raised its stake in shares of SpringWorks Therapeutics by 47.9% in the second quarter. First Horizon Advisors Inc. now owns 1,183 shares of the company’s stock valued at $45,000 after buying an additional 383 shares during the period. Allspring Global Investments Holdings LLC bought a new stake in SpringWorks Therapeutics in the 2nd quarter valued at about $123,000. CANADA LIFE ASSURANCE Co lifted its holdings in SpringWorks Therapeutics by 20.3% during the first quarter. CANADA LIFE ASSURANCE Co now owns 4,465 shares of the company’s stock valued at $220,000 after purchasing an additional 754 shares during the last quarter. SG Americas Securities LLC boosted its position in SpringWorks Therapeutics by 8.3% during the first quarter. SG Americas Securities LLC now owns 4,673 shares of the company’s stock worth $230,000 after purchasing an additional 358 shares during the period. Finally, Farallon Capital Management LLC purchased a new position in shares of SpringWorks Therapeutics in the first quarter worth about $246,000.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on SWTX shares. Wedbush reaffirmed an “outperform” rating and issued a $77.00 price target on shares of SpringWorks Therapeutics in a report on Thursday. JPMorgan Chase & Co. upped their price target on SpringWorks Therapeutics from $64.00 to $68.00 and gave the company an “overweight” rating in a research report on Wednesday, September 4th. Finally, HC Wainwright reissued a “buy” rating and issued a $76.00 price target on shares of SpringWorks Therapeutics in a report on Wednesday, August 28th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $68.50.

SpringWorks Therapeutics Price Performance

Shares of SWTX stock opened at $33.99 on Friday. The business has a 50-day moving average of $33.26 and a 200 day moving average of $37.48. SpringWorks Therapeutics, Inc. has a 1-year low of $18.00 and a 1-year high of $53.92. The stock has a market capitalization of $2.52 billion, a PE ratio of -7.67 and a beta of 0.79.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.58. The firm had revenue of $59.73 million during the quarter, compared to analysts’ expectations of $34.42 million. SpringWorks Therapeutics’s revenue was up 59732900.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.25) EPS. Analysts anticipate that SpringWorks Therapeutics, Inc. will post -3.36 EPS for the current year.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.